Keryx Biopharmaceuticals


Roth Capital Reiterates Buy On Keryx Following 3Q14 Results; Keeps $32 PT

In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a …

Brean Capital Maintains Buy On Keryx Biopharmaceuticals On The Back Of 3Q14 Update

In a research report released today, Brean Capital analyst Jonathan Aschoff maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price …

Maxim Maintains Buy On Keryx As Nephrology Conference Papers Show Cost Savings And LT Benefits Of Ferric Citrate

In a research note issued this morning, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, …

Keryx: Will NCE Matter? Roth Capital Doesn’t Think So; Reiterates Buy

In a report issued to investors this morning, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $32 …

Maxim Assigns Buy On Keryx Following Issuance Of Additional Patent On Ferric Citrate

In a research note published today, Maxim Group analyst Jason Kolbert assigned a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as …

Brean Capital Comments On Keryx Following Issuance Of A New U.S. Patent

In a research note published today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $26 price target, as the …

H.C. Wainwright Reiterates Buy On Keryx Following Initiation Of A New Phase 3 Study

In a research report released today to investors, H.C.

Maxim Raises Keryx Price Target To $26 Following Ferric Citrate Pricing

In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) and slightly raised his …

Roth Capital Maintains Bullish Stance On Keryx Following Phase 3 Initiation in CKD

In a research note published today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Keryx Biopharmaceuticals (NASDAQ:KERX) with a $32 price target, in light …

H.C. Wainwright Remains Bullish On Keryx Following Ferric Citrate FDA Approval

In a research report issued today, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts